Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-08-31

Study Completion Date

2005-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is conducted in Asia. The aim of this trial is to investigate pharmacokinetics of insulin detemir in healthy Taiwanese subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects

NCT01498939

Diabetes Healthy

COMPLETED PHASE1

Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

NCT01497600

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE1

Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus

NCT01709929

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

COMPLETED PHASE3

Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes

NCT01497574

Diabetes Diabetes Mellitus, Type 1

COMPLETED PHASE1

A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works

NCT05134987

Diabetes Mellitus, Type 1

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Insulin detemir

Group Type EXPERIMENTAL

insulin detemir

Intervention Type DRUG

Single dose, 0.5 U/kg, administered s.c. (under the skin)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

insulin detemir

Single dose, 0.5 U/kg, administered s.c. (under the skin)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Considered generally healthy upon completion of medical history and physical examination as judged by the investigator
* Body mass index (BMI) between 18 and 27 kg/m\^2, inclusive
* Fasting plasma glucose maximum 6.1 mmol/l
* Non-smoker or smoking maximum 5 cigarettes per day or the equivalent

Exclusion Criteria

* Participation in any other clinical trial involving other investigational products within the last 3 months
* Subject with a history of alcohol or drug dependence
* Subject with a first-degree relative with diabetes mellitus

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No